Pfizer (PFE)

Try not to let market volatility bring you down. Instead, let dividend stocks make you happy. These high-yield dividend stocks will pay you between 3% and 7% to hold them.

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Friday and discover the stocks that are dominating the trading activity and setting the pace for the market.

With the market pullback, many quality dividend stocks are buying opportunities near their 52-week lows.

For many investors, dividend-focused stocks and funds provide a way to generate passive income, whether to supplement retirement, cover day-to-day

NICE recommended Pfizer's Adcetris for NHS use in advanced Hodgkin lymphoma, citing strong trial data and a new discount agreement with Takeda.

Though the FDA was set to give full approval to the vaccine, senior leaders at the agency have now said that the company’s application needs more data and is unlikely to be approved soon, The Wall Street Journal reported.

Big Pharma, Big Tech and REIT is on the value menu. Discount opportunities at this level are rare.

Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest and driving market movements.

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday.

Reports of mass firings include another high-profile official as Robert F. Kennedy Jr. and Marty Makary take up their new roles.

JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.

The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.

Value stocks are outperforming flashy growth rivals due to market uncertainty, making value-based ETFs a good bet for steady income and diversification.

Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious vaccine-related adverse events.

CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in July 2025.